Semaglutide Demonstrates Benefits Across Frailty Levels

“What was less expected was that persons with frailty appeared to derive greater benefits on how they felt and functioned (eg, mobility appeared to improve more with semaglutide in persons with frailty); and that, compared with placebo, persons with greater frailty were actually less likely to discontinue semaglutide due to safety events over time. These findings, together, suggest the benefit-risk balance of semaglutide can be favorable even in persons with frailty.”

“Our hypothesis was that the benefits of semaglutide on clinical events would appear consistent across frailty categories. Hence, we are not necessarily surprised by this finding, but certainly reassured.”

“This is an important message of reassurance.”